Mipomersen Sodium

Drug #2301

Mipomersen sodium is an oligonucleotide inhibitor of apo B-100 synthesis. ApoB is the principal apolipoprotein of LDL and its metabolic precursor, very low density lipoprotei (VLDL). Mipomersen inhibits synthesis of apoB by sequence-specific binding to its messenger ribonucleic acid (mRNA) resulting in degradation of the mRNA through enzyme-mediated pathways or disruption of mRNA function through binding alone. It is used as adjunct to lipid lowering medications and diet to reduced low density lipoprotein cholestrol(LDL C) Apolipoprotein B, total cholestrol(TC) and non high density lipoproteincholestrol (Non HDL C) in patient with Homozygous Familial HyperCholesterolemia(HOFH)

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to phosphorothioate oligonucleotide sodium salt.

It belongs to Lipid lowering agents pharmacological group on the basis of mechanism of action.

Molecular Weight: 7594.9 · Solubility in Water: freelysoluble · Solubility in Alcohol: soluble in methnol · Non-proprietary name: MIPOMERSEN Na.

Molecular structure of Mipomersen Sodium

Pharmacokinetics

Absorption: Mipomersen Sodium has an oral bioavailability is 66% (±12%).

Distribution: Mipomersen Sodium has a plasma protein binding is 90%.

Elimination: it is metabolised via tissue, plasma half-life is 1 to 2 months, renal excretion is in urine.

Indications

Mipomersen Sodium is primarily indicated in conditions like Homozygous familial hypercholesterolemia.

Contraindications

None recorded.

Dosage

Mipomersen Sodium's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
200 mg	200 mg	—	SC	Do not administer intramuscularly or intravenously
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Mipomersen Sodium is known to cause more or less tolerable side effects which are usually transient. These include elevation in serum transaminases, Flu like symptoms, Headache, Injection site reactions, Nausea.

Warnings / Precautions

De to risk of hepatic toxicity, before beginning treatment, measure transaminases (ALT, AST), alkaline phosphatase, and total bilirubin . injection site reactions like erythema, pain, tenderness, pruritus and local swelling, Flu-like symptoms such as influenza like illness, pyrexia, chills, myalgia, arthralgia, malaise or fatigue, which typically occur within 2 days after an injection,

Available Brands

None recorded.

Storage Conditions

Mipomersen Sodium should be stored Injection.

Drug Classification

1.12.6 — Lipid-regulating drugs /Anti-atheromas